{"brief_title": "Safety and Efficacy of Insulin Detemir Plus Insulin Aspart Against Insulin Glargine Plus Insulin Aspart as Mealtime Insulin in Type 1 Diabetes", "brief_summary": "This trial is conducted in Europe and the United States of America (USA). The purpose of this study is to test whether insulin detemir is a safe and at least as effective alternative to insulin glargine for the control of blood glucose in basal/bolus therapy in patients with type I diabetes.", "condition": "Diabetes Mellitus, Type 1", "intervention_type": "Drug", "intervention_name": "insulin aspart", "criteria": "Inclusion Criteria: - Type 1 diabetes for at least 12 months - Current treatment with basal-bolus insulin regimen for more than or equal to 3 months - HbA1c less than or equal to 11.0% Exclusion Criteria: - Proliferative retinopathy or maculopathy - Recurrent major hypoglycaemia - Impaired hepatic or renal function - Cardiac problems or uncontrolled hypertension", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "id": "NCT00095082.xml"}